T he ␣ 1B -adrenergic receptor (AR) is a member of the G protein-coupled receptor family and is the predominant ␣ 1 AR subtype expressed in adult rodent myocardium. 1,2 ␣ 1 AR agonists, including phenylephrine (PE), have been shown to mediate intracellular responses through ␣ 1 AR activation of the heterotrimeric G protein Gq, which in turn activates the effector enzyme phospholipase C (PLC). Activation of the ␣ 1 AR-Gq-PLC pathway results in the cellular accumulation of inositol 1,4,5-trisphosphate and diacylglycerol (DAG), leading to increased intracellular calcium and protein kinase C activity. 3 The role of ␣ 1 ARs in the heart is not well understood; however, the Gq-PLC-protein kinase C pathway is important in initiating the hypertrophic response. 4 In fact, we have recently shown, using transgenic (Tg) mice, that signaling through Gq is the final common trigger of in vivo pressure overload ventricular hypertrophy. 5 Activation of ␣ 1 ARs in cultured neonatal ventricular myocytes has been shown to induce an embryonic program of gene expression, including ventricular expression of atrial natriuretic factor (ANF), and cell hypertrophy without hyperplasia. 6, 7 Moreover, adult Tg mice expressing a constitutively activated mutant (CAM) of the ␣ 1B AR in a cardiac-specific manner have elevated myocardial DAG content, ventricular ANF expression, and myocardial hypertrophy, as measured by increased heart-to-body weight ratio and myocyte crosssectional area. 8 Thus, constant stimulation of the ␣ 1B AR in vivo is sufficient to induce a hypertrophic phenotype independent of hemodynamic changes.
Signaling through ␣ 1 ARs is regulated, like that mediated by many other G protein-coupled receptors, via phosphorylation and the triggering of desensitization mechanisms. 9 Phosphorylation of agonist-occupied ␣ 1 ARs is accomplished by members of the serine/threonine G protein-coupled receptor kinase (GRK) family. Three predominant GRKs are expressed in the mammalian heart, as follows: GRK2 (com-monly known as the ␤-AR kinase [␤ARK1]), GRK3 (␤ARK2), and GRK5. 10 Although many studies have been done in vitro concerning the actions of GRKs on receptor signaling, almost nothing in vivo has been done to elucidate substrate specificity of GRKs. In fact, in vitro studies with several receptor systems important in the heart have revealed no definitive GRK selectivity. [11] [12] [13] [14] In vitro studies examining ␣ 1B ARs have found that GRK2 and GRK3 could both increase agonist-induced phosphorylation of the ␣ 1B AR and promote desensitization of signaling, whereas GRK5 increased the basal phosphorylation of ␣ 1B ARs without any effect of agonist-stimulated phosphorylation. 12 More recently, however, GRK substrate selectivity has been identified in vitro, as Iacovelli et al 15 described the way in which GRK2 stably transfected into rat thyroid FRTL-5 cells desensitized endogenous thyrotropin receptors, whereas GRK5 and GRK6 did not. Additionally, GRK2 had variable effects on the G␣i-coupled A 1 adenosine receptor. Adenylate cyclase inhibition was unaffected, but mitogen-activated protein kinase (MAPK) signaling was attenuated by GRK2 overexpression. 15 Importantly, and in contrast to Diviani et al, 12 Iacovelli et al 15 also found that GRK2 overexpression did not alter ␣ 1B AR signaling. Thus, this suggests that there may be cell-type specificity of the GRKs for their various substrates, making it essential to understand the in vivo selectivity of these kinases in the appropriate cells/tissues of interest.
Recently, the use of Tg mice with cardiac-specific overexpression of GRK2, GRK3, or GRK5 have made it possible to address in vivo, tissue-specific GRK substrate selectivity. 16 -18 The CAM␣ 1B AR and GRK Tg mice provide a unique and powerful opportunity to create hybrid Tg mice to study the specific interactions in vivo between these 3 individual GRKs and ␣ 1B ARs. In the present study, the hearts of these hybrid mice were used as novel "in vivo reaction vessels" to determine the in vivo selectivity of GRK2, GRK3, and GRK5 for myocardial ␣ 1B ARs. Furthermore, these mice were used to elucidate a possible role of ␣ 1B AR desensitization in the control of myocardial hypertrophy. These results reinforce that it is essential to verify in vitro findings in vivo in the context of the whole organism to begin to understand the true complexity of the mammalian cardiovascular system.
Materials and Methods

Experimental Animals
Myocardial-specific overexpression of the corresponding transgene was targeted by the ␣-myosin heavy chain (␣MyHC) gene promoter as previously described. 19 Each of the single-Tg mouse lines used as parental crossbreeders has previously been described as noted in the Table, except for GRK2-20. All Tg lines were originally generated in C57BL/6 mice. To generate the GRK2-20 mouse, a GRK2 Tg construct was prepared by inserting the complete open reading frame of bovine GRK2 into pGEM containing a 5.5-kb SacI/SalI fragment from the ␣MyHC promoter and the simian virus 40 intron-poly A. Tg animals were screened by Southern blot and polymerase chain reaction analysis of tail clip DNA.
Hybrid double-Tg mice were created by mating single-Tg mice together as described in the Table. The animals in this study were handled according to approved protocols and animal welfare regulations at Duke University Medical Center.
Radioligand Binding
Tg mouse heart crude membranes were prepared as described. 19 
Protein Immunoblotting
Immunodetection of GRK2 and GRK3 was carried out first with an immunoprecipitation using a monoclonal GRK2/GRK3 antibody, as described previously. 18 GRK5 was detected in crude membrane protein extracts. 17 Heart Weight-to-Body Weight Ratio
Mice were first anesthetized 21 and weighed, and their hearts were quickly excised, blotted dry, weighed, and frozen in liquid N 2 . Heart weight-to-body weight ratios were calculated and expressed in mg/g. 21 
Ventricular ANF mRNA Analysis
The apical portion of the left and right ventricles of frozen hearts obtained as described above was homogenized, total RNA was extracted using an Ultraspec solution (Biotecx Laboratories), and Northern analysis was performed as previously described. 8, 20 After ANF detection, all blots were stripped and reprobed with a rat 
DAG Quantification
Lipid fractions from frozen hearts were extracted as described. 8,20 32 P-labeled phosphatidic acid (phosphorylated DAG) was isolated by silica gel thin-layer chromatography and quantified with the PhosphorImager. DAG content was normalized to tissue phospholipid, and the final DAG concentration was expressed as pmol of DAG/ nmol of lipid phosphate, as described previously. 8, 20 
MAPK Activity
Mice were given a 200-L intraperitoneal injection of 500 mol/L PE or saline. After 10 minutes, mice were anesthetized as described above and hearts were quickly removed and frozen. Excised hearts were prepared as described previously. 5, 18 Immunoprecipitations were performed using anti-extracellular signal-regulated kinase (ERK2) or anti-c-jun N-terminal kinase (JNK1) antibody (Santa Cruz Biotechnology). Kinase assays were carried out at 30°C for 15 minutes 5,18 using myelin basic protein (MBP) (for ERK2) with glutathione S-transferase-c-jun (JNK1) as a substrate.
Statistical Analysis
Data are expressed as meanϮSEM. An unpaired 2-tailed Student t test was performed for all biochemical data. For all analyses, PϽ0.05 was considered statistically significant.
Results
Transgene Expression
The Table lists the 15 lines of myocardium-targeted Tg mice used throughout this study, including parental single-Tg mice and the resultant hybrid double-Tg offspring. Included is the documented overexpression levels compared with the endogenous myocardial proteins. Two separate lines of GRK2 animals were used; one line, GRK2-3, has been previously described, 16, 17 and the other is an as-yet-unreported GRK2 mouse line, GRK2-20, with Ϸ20-fold enhancement of GRK activity as compared with endogenous GRK2 activity. Figure  1A illustrates the relative kinase activity that each of the single-Tg lines has in comparison with the others versus non-Tg littermate control (NLC). The primary GRK activity in the mouse heart is GRK2 22 ; however, all of the kinases are equally capable of phosphorylating rhodopsin. Each transgene constitutes the majority of activity when overexpressed in the heart. Whereas the Table describes overexpression levels of the various GRKs with respect to their endogenous levels, when expressed in comparison with total NLC GRK activity, Tg GRK2-3 has Ϸ3-fold, TgGRK2-20 has Ϸ20-fold, TgGRK3 has Ϸ5-fold, and TgGRK5 has Ϸ20-fold overexpression in activity ( Figure 1A ). Hybrid Tg mice were examined to verify that both transgenes were expressed at equivalent levels as found in the single-Tg parental lines. Importantly, we found no change in expression in any of the transgene protein products in hybrid mice. For example, as shown in Figure 1 , protein immunoblotting revealed no difference in the level of overexpression of GRK2 or GRK3 when comparing hearts from GRK2-3 or GRK3 with CAM␣ 1B /GRK2-3 and CAM␣ 1B /GRK3 hearts ( Figure 1B ). Similar results were found in hybrid Tg mice overexpressing GRK5 ( Figure 1C ) and the GqI (data not shown). Furthermore, endogenous GRK levels were not altered in the CAM␣ 1B AR mice ( Figure 1B and 1C). We also verified that GRK activity was not compromised in the hybrid Tg mice. In vitro GRK phosphorylation assays illustrate that phosphorylation activity was similar in single-Tg and hybrid Tg mice (data not shown). As shown in Figure 1D , myocardial ␣ 1 AR density in the hybrid CAM␣ 1B AR and the various GRKoverexpressing lines of Tg mice was equal to single-Tg CAM␣ 1B AR mouse myocardial ␣ 1 AR levels. The myocardial ␣ 1 AR density in the different GRK-overexpressing lines of Tg mice was equal to endogenous levels found in NLC mice (data not shown). The ␣ 1 AR overexpression seen in the wild-type (WT) ␣ 1B AR was preserved in the presence of all second transgenes in the hybrid lines (data not shown).
In Vivo Inhibition of Hypertrophy
CAM␣ 1B AR mice have an elevated heart-to-body weight ratio compared with NLC mice (Figure 2 ), consistent with earlier findings that demonstrated that these mice had myocardial hypertrophy. 8 When the CAM␣ 1B AR mice were crossed with animals overexpressing GRK2 (3-fold or 20-fold), the heartto-body weight ratio remained elevated (Figure 2) . However, the presence of GRK3 overexpression in the CAM␣ 1B /GRK3 animals ablated CAM␣ 1B AR-induced hypertrophy, as did concomitant GRK5 overexpression ( Figure 2 ). Thus, GRK3 and GRK5 overexpression were each capable of attenuating CAM␣ 1B AR-induced hypertrophy, whereas increased cardiac GRK2 activity had no effect.
To verify that myocardial hypertrophy seen in the CAM␣ 1B AR animals is the result of enhanced Gq signaling, we created hybrid Tg mice with CAM␣ 1B AR overexpression and overexpression of a peptide inhibitor of the receptor-Gq interface. This peptide (GqI) represents the last 54 amino acids of murine G␣q(305-359) and has been shown to specifically inhibit Gq signaling in vivo. 5 Similar to CAM␣ 1B / GRK3 mice, CAM␣ 1B /GqI animals had a heart-to-body weight ratio equal to that of NLCs, demonstrating that signaling through Gq is responsible for the CAM␣ 1B AR phenotype.
CAM␣ 1B AR Induced DAG Activation
Specific interactions between GRKs and ␣ 1B ARs in vivo should result in attenuated signal transduction because of receptor desensitization, and this could account for the inhibition of CAM␣ 1B AR-induced hypertrophy by overexpression of GRK3 and GRK5. Signaling through ␣ 1B AR-Gq proceeds through PLC activation, resulting in DAG accumulation. Therefore, basal DAG content was quantified in lipid fractions of hearts from Tg mice. Myocardial DAG content was significantly elevated 60% in CAM␣ 1B AR hearts ( Figure  3 ), consistent with previous data. 8 (Figure 3) . Thus, like hypertrophy, CAM␣ 1B AR signaling is not altered by GRK2 overexpression. In contrast to these results, myocardial DAG content was significantly lowered in hybrid CAM␣ 1B /GRK3 mice compared with CAM␣ 1B AR animals demonstrating that signaling through CAM␣ 1B ARs is attenuated by GRK3 overexpression ( Figure 3) .
Interestingly, and in contrast to the results seen in the heart-to-body weight ratios, hybrid CAM␣ 1B /GRK5 mice still had significantly elevated myocardial DAG content, similar to levels seen in CAM␣ 1B AR and CAM␣ 1B /GRK2 animals ( Figure 3) . To further study the interactions between GRK5 and ␣ 1B ARs in vivo, we generated hybrid myocardiumtargeted Tg mice overexpressing the WT␣ 1B AR and GRK5 (Table) 20 In hybrid WT␣ 1B /GRK5 mice, myocardial DAG content was still significantly elevated above NLC at a level similar to that of WT␣ 1B AR mice (4.98Ϯ0.54, nϭ6). Thus, it appears that although GRK5 expression was capable of inhibiting the development of ␣ 1B -induced hypertrophy, it does not affect Figure 2 . In vivo inhibition of CAM␣ 1B ARinduced hypertrophy. Hearts were excised, weighed, and normalized to total body weight and expressed as a meanϮSEM of the (mg/g) ratio. Number of individual mice per group were as follows: NLC, nϭ13; TgCAM␣ 1B AR, nϭ13; TgCAM␣1B/GRK2-3, nϭ10; TgCAM␣ 1B /GRK2-20, nϭ9; TgCAM␣ 1B /GRK3, nϭ8; TgCAM␣ 1B /GRK5, nϭ7; and TgCAM␣ 1B / GqI, nϭ5. *PϽ0.05 vs NLC, †PϽ0.05 versus TgCAM␣ 1B AR. Figure 3 . In vivo GRK influence on basal CAM␣ 1B AR-induced DAG content. Lipid extraction was performed on NLC, singleTg, and hybrid Tg mouse hearts as described in Materials and Methods. DAG content was quantified using 50 nmol of lipid phosphate as described. A, Representative autoradiogram of thin-layer chromatography results from DAG assay in listed mice. B, Quantification of basal DAG activity expressed as meanϮSEM. Number of mice examined per group was as follows: NLC, nϭ4; TgCAM␣ 1B AR, nϭ5; TgCAM␣ 1B /GRK2-3, nϭ5; TgCAM␣ 1B /GRK2-20, nϭ4; TgCAM␣ 1B /GRK3, nϭ5; and TgCAM␣ 1B /GRK5, nϭ6. *PϽ0.05 vs NLC, †PϽ0.05 vs TgCAM␣ 1B AR.
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basal ␣ 1B AR/PLC signaling in the heart as examined in vivo after either WT or CAM␣ 1B AR overexpression.
Ventricular ANF mRNA
A central molecular characteristic of ventricular hypertrophy is the upregulation of a number of genes normally expressed in fetal myocardium. This includes ventricular expression of ANF. To investigate this in our series of hybrid Tg mice, we performed Northern blots on ventricular RNA, normalizing mouse ANF expression to an internal control, GAPDH (see Materials and Methods). Ventricles from NLC mice and the single GRK-overexpressing Tg mice demonstrated very faint or undetectable ANF mRNA expression, which was consistent with inactivation of this gene in normal adult ventricular myocardium (data not shown). We found that ventricular ANF mRNA levels were increased Ϸ700% in CAM␣ 1B AR mice (Figure 4) , which is similar to previous findings. 8 Hybrid CAM␣ 1B /GRK2 ventricles still exhibited enhanced ANF mRNA levels that actually were, for reasons unknown, even higher than those of CAM␣ 1B AR mice for the TgGRK2-3, whereas CAM␣ 1B /GRK2-20 mice had ANF levels equivalent to those of CAM␣ 1B AR mice (Figure 4) . Conversely, CAM␣ 1B /GRK3 animals had ventricular ANF mRNA levels equal to NLC values (Figure 4 ). This attenuation of ANF mRNA levels induced by CAM␣ 1B AR overexpression was also seen in hybrid CAM␣ 1B /GqI mice ( Figure  4 ), demonstrating that Gq coupling is responsible for triggering this ANF response. Thus, as with hypertrophy and DAG signaling, GRK3 overexpression attenuates the CAM␣ 1B AR phenotype, whereas GRK2 overexpression does not significantly alter the CAM phenotype. Interestingly, CAM␣ 1B /GRK5 mice exhibited lower ventricular ANF expression (350Ϯ70% of NLC, nϭ3) compared with that of CAM␣ 1B AR mice (570Ϯ50% of NLC, nϭ9), although this attenuation was not statistically significant ( Figure 4) . Moreover, the ANF mRNA levels were still significantly higher than levels seen in NLC mice, suggesting that GRK5 overexpression does not totally block CAM␣ 1B AR-induced ANF expression. To further examine the effects of GRK5 on ␣ 1B ARGq-mediated ventricular ANF induction, we studied ANF expression in WT␣ 1B AR mice and WT␣ 1B /GRK5 animals. WT␣ 1B AR mice also exhibited elevated ventricular ANF mRNA levels (505Ϯ51% of NLC [nϭ5]; PϽ0.05). Interestingly, we have previously shown that this occurs without any myocardial hypertrophy. 20 Consistent with findings shown in Figure 4 , hybrid WT␣ 1B /GRK5 mice also had significantly enhanced ventricular ANF mRNA (492Ϯ53% of NLC [nϭ5]; PϽ0.05), demonstrating that GRK5 does not eliminate ANF expression after enhanced ␣ 1B AR-Gq signaling. WT␣ 1B /GRK2-3 also had maintained elevated ANF expression (555Ϯ49% of NLC [nϭ3]; PϽ0.05), suggesting that regulation of ␣ 1B AR by GRKs is similar for both the WT and CAM␣ 1B AR and that GRK2 does not affect ␣ 1B AR signaling in the heart.
ERK and JNK Activity in Response to ␣ 1 AR Activation and GRK Expression
Because the data presented above demonstrate that there is apparent specificity among GRK2, GRK3, and GRK5 in desensitizing ␣ 1B ARs in vivo in the heart, we examined the effects of these 3 GRKs on endogenous myocardial ␣ 1 AR signaling. A relevant signaling pathway that has been demonstrated to be activated by ␣ 1 AR stimulation in the heart is the MAPK pathway, including ERK1/ERK2 and JNK1. [23] [24] [25] In this study, we used ERK and JNK activity assays to determine whether endogenous in vivo myocardial ␣ 1 AR-MAPK signaling is altered in GRK Tg mice. Mice were injected intraperitoneally with either saline (basal signaling) or the ␣ 1 -agonist PE, and ERK and JNK activity induced by PE (over basal activity) was determined in the GRK Tg animals and compared with values in NLC mice. After 10 minutes, injected mice were euthanized, their hearts extracted and homogenized, and ERK and JNK were immunoprecipitated for an in vitro kinase assay. Basal ERK and JNK activity measured after saline injection was similar or equivalent in NLC and single GRK-overexpressing mice (data not shown). In NLC mice, PE induced a significant 40% increase in ERK activity over basal levels of activity ( Figure 5A ). As shown in Figure 5A , GRK2 overexpression in either the GRK2-3 or GRK2-20 animals did not inhibit myocardial PE-induced ERK activity, whereas GRK3 or GRK5 overexpression significantly attenuated PE-induced ERK activity. Similar to the ERK activity results, JNK activity was attenuated in mice overexpressing GRK3, whereas GRK2 overexpression at either low or high amounts had no impact on JNK signaling Signals from the ANF blots were counted on a Molecular Dynamics PhosphorImager and normalized to GAPDH levels. GAPDH mRNA levels were similar in all ventricular samples from the different mice tested. Data shown are meanϮSEM for the ANF signal corrected by GAPDH and expressed as a percentage of the ANF/GAPDH signal for NLC. Number of mice examined for each group was as follows: NLC, nϭ8; TgCAM␣ 1B AR, nϭ9; TgCAM␣ 1B /GRK2-3, nϭ4; TgCAM␣ 1B /GRK2-20, nϭ5; TgCAM␣ 1B /GRK3, nϭ4; TgCAM␣ 1B /GRK5, nϭ3; and TgCAM␣ 1B / GqI, nϭ4. *PϽ0.05 vs NLC, †PϽ0.05 vs TgCAM␣ 1B AR.
induced by the ␣ 1 AR agonist PE ( Figure 5B) . Similar to what was seen with ANF signaling (Figure 4 ), GRK5 overexpression attenuated JNK signaling only partially as compared with NLC activation ( Figure 5B ). These data further suggest that GRK3 is the primary GRK responsible for desensitizing in vivo ␣ 1 AR signaling in the heart. GRK5 had variable effects on ␣ 1B AR signaling, and the complexity of GRK5 regulation of in vivo ␣ 1B AR signaling remains to be fully elucidated.
Discussion
The results of this study, which uses 15 distinct Tg mouse lines, reveal 2 significant findings. The first is the demonstration of the feasibility and power of using hybrid Tg mice with myocardial overexpression of G protein-coupled receptors with concomitant GRK overexpression to specifically study their in vivo interactions. Secondly, this hybrid Tg strategy revealed that myocardial ␣ 1 ARs are in vivo targets for GRK3-mediated desensitization but not for GRK2, the GRK most abundantly expressed in the myocardium. These differing effects of GRK2 and GRK3 were confirmed in hybrid Tg mice overexpressing either the WT ␣ 1B AR or a CAM ␣ 1B AR, as well as in studies designed to examine endogenous myocardial ␣ 1 AR signaling. The effects of these GRKs were assessed on the hypertrophic phenotype of these mice, Gq-PLC signaling (via myocardial DAG content), and endogenous ␣ 1 AR-MAPK signaling in the heart. In addition to the differing results found with these 2 GRKs, overexpression of GRK5 caused variable effects on in vivo ␣ 1B AR signaling. GRK5 was capable of attenuating endogenous ␣ 1 AR-mediated ERK activity and CAM␣ 1B AR-induced hypertrophy. However, it had a lesser effect on CAM and WT␣ 1B AR-mediated DAG levels, ventricular ANF mRNA expression, and JNK activity.
The hearts of these hybrid Tg mice were used in this study as novel "in vivo reaction vessels," making it possible to study the biochemical and physiological consequences of the actions of one transgene product (ie, GRK) on another (ie, ␣ 1B AR). This study has demonstrated the power of this simple crossbreeding strategy that can be used to address questions regarding GRK specificity on other receptors or for dissecting individual phenotypes of other Tg models. Importantly in this study, expression levels of ␣ 1B ARs and individual GRKs driven by the same ␣MyHC promoter, when expressed concomitantly in the hybrid mice, did not differ from the levels of overexpression seen in the individual Tg parental lines. This is an important finding, given that promoter competition might be expected to occur, limiting the overexpression of 1 or both of the transgenes, and thus limiting the usefulness of this strategy. Furthermore, our previous studies of Tg mice using the ␣MyHC promoter have demonstrated that transgene expression was homogenous in nature throughout the heart 8, 16 ; thus, both transgenes should be expressed in a similar fashion when together.
Using these hybrid Tg mice in this study allowed us to investigate the in vivo specificity of GRK2 (also known as ␤ARK1), GRK3 (␤ARK2), and GRK5 on ␣ 1B ARs in the heart. This is an area of study concerning the 6-member GRK family, for which definitive information has been lacking. A majority of in vitro experiments using heterologous cell culture expression systems with a variety of overexpressed G protein-coupled receptors have shown limited substrate selectivity for these 3 ubiquitously expressed GRKs. 10 -14 Importantly in the present study, we have revealed that these 3 GRKs differ in their ability to desensitize ␣ 1 ARs in vivo in the heart. Our study differs from previous in vitro findings regarding the ␣ 1B AR using heterologous cell culture expression systems, in which overexpression of either GRK2 or GRK3 promoted ␣ 1B AR desensitization via agonist-induced phosphorylation. 12 Our results demonstrate that GRK2 is ineffective in regulating either the overexpressed CAM␣ 1B AR or the WT␣ 1B AR, and more importantly, signaling through endogenous myocardial ␣ 1 ARs (of which the predominant subtype in the mouse heart is the ␣ 1B 1 ) was also unaltered by GRK2 overexpression. Interestingly, signaling through each type of ␣1BAR in the different hybrid Tg mice was significantly attenuated by GRK3 overexpression demonstrating an in vivo selectivity between GRK2 and GRK3 in the heart. Similar to Diviani et al, 12 we found variable effects of GRK5 on agonistmediated desensitization of myocardial ␣ 1B ARs. Importantly, levels of GRK overexpression, as compared with total endogenous NLC GRK activity, between the different Tg mice could not explain the lack of GRK2 effect, given that neither Ϸ3-fold GRK2 overexpression nor Ϸ20-fold GRK2 overexpression was sufficient to attenuate in vivo ␣ 1B AR signaling, whereas Ϸ5-fold GRK3 overexpression (Ϸ12-fold overexpression when compared with endogenous GRK3 levels) effectively abrogated all examined forms of ␣ 1B AR signaling and eliminated the myocardial hypertrophy induced by CAM␣ 1B AR expression. Recently, it was shown by Iacovelli et al 15 in FRTL-5 cells stably overexpressing GRK2 that endogenous signaling through ␣ 1B AR was not attenuated, whereas signaling through endogenous thyrotropin receptors was. Thus, there are now data to suggest that even in certain cell types in vitro, GRK2 does not desensitize the ␣ 1B AR, which is consistent with our in vivo findings in the heart.
Despite their initial characterization as highly homologous isozymes, a pattern of in vivo differences between GRK2 and GRK3 is now emerging. In addition to our current findings concerning ␣ 1B AR signaling, we have demonstrated previously that GRK3 does not, whereas GRK2 does, regulate endogenous ␤AR signaling in the heart. 18 As is the case with ␣ 1B AR signaling, these in vivo ␤AR findings differ from in vitro results that demonstrate that both GRK2 and GRK3 phosphorylate and desensitize ␤ 1 ARs, the primary ␤AR subtype expressed in the myocardium. 11 Furthermore, studies with TgGRK3 animals reveal GRK specificity for the endogenous myocardial thrombin receptor. 18 The thrombin receptor is one receptor in which a distinct difference in GRK-mediated desensitization has been shown to exist in vitro between GRK2 and GRK3. 26 Differences in the in vivo myocardial regulation of angiotensin II receptors have also been seen in TgGRK3 and TgGRK2 mice. 17, 18 Thus, the use of Tg technology has begun to clarify GRK specificity in the in vivo heart. Collectively, these data suggest that GRK2 and GRK3 have distinct substrates in the intact heart and do not exhibit redundancy in the normal regulation of myocardial function.
The regulation of GRK2 and GRK3 may provide insight into why these highly homologous kinases differ in their in vivo substrate selectivity in the heart. Both GRK2 and GRK3 are cytosolic enzymes that undergo a membrane-targeting event before their phosphorylation of agonist-occupied receptors. 9, 10 For these 2 GRKs, this is accomplished by a specific proteinprotein interaction between the carboxyl-terminal domain of GRK2 and GRK3 and G ␤␥ subunits released from activated heterotrimeric G proteins. 27, 28 Interestingly, the most divergent region between GRK2 and GRK3 is within the mapped G ␤␥ binding domain. 28 -30 This may indicate differential affinities of these 2 GRKs for G ␤␥ subunits, and the availability of G␤␥s may be influenced by cell type and by the G protein-coupled receptor activated. Thus, G ␤␥ s released after myocardial ␣ 1B AR stimulation may bind to GRK3 with higher affinity than that for GRK2, and vice versa for G ␤␥ s released by ␤ 1 ARs in vivo.
Importantly, in vitro evidence supports the notion that GRK2 and GRK3 can be targeted to membranes in a receptor-and G ␤␥ -dependent manner. 31 Although the in vivo G protein-coupled receptor specificity for GRK2 and GRK3 is becoming clearer, the understanding of in vivo GRK5 actions in the heart are more complex. It has been shown that in contrast to GRK2 overexpression, myocardial GRK5 overexpression, like that of GRK3, does not alter in vivo angiotensin II signaling. 17 However, like GRK2 overexpression, ␤AR signaling in vivo was significantly attenuated in the hearts of TgGRK5 mice. 17 The present results reveal conflicting findings regarding the in vivo actions of GRK5 on myocardial ␣ 1B AR signaling. Whereas in vivo GRK5 attenuated CAM␣ 1B AR-induced hypertrophy and endogenous ␣ 1B AR agonist-stimulated ERK2 activity, GRK5 was incapable of inhibiting overexpressed CAM␣ 1B AR-or WT ␣ 1B AR-induced DAG and TgWT␣ 1B ARinduced ANF levels, and only partially attenuated ANF levels in the TgCAM␣ 1B AR hearts and JNK1 activity in the hearts expressing endogenous ␣ 1B ARs. These results suggest that DAG signaling due to ␣ 1B AR stimulation does not result in hypertrophy and that ventricular ANF expression, although concomitant with it, is not sufficient for hypertrophy. In fact, recent studies associate ANF with inhibition of proliferation of nonmyocardial cells and antihypertrophic effects in cardiomyocytes. [32] [33] [34] [35] In contrast, it appears that MAPK activation in response to ␣ 1B AR-Gq stimulation may be important for hypertrophy. In fact, these findings may shed light on the specific signaling pathways responsible for the progression of ␣ 1B AR activation to myocardial hypertrophy, although this remains to be determined.
G protein-coupled receptors play integral roles in cardiac function, and examination of their regulation by GRKs is important for understanding cardiac homeostasis and the regulation of compensation during disease states. For example, heart failure is associated with a constellation of changes, including increases in circulating catecholamines, decreases in ␤AR density, and increases in GRK2. 36 Additionally, ␣ 1 AR density has been shown to be elevated when heart failure develops. 37 Therefore, in disease states when ␤ARs are downregulated, ␣ 1 ARs become a more predominant population of the myocardial ARs. Importantly, as the findings regarding in vivo GRK substrate specificity in this report reveal, potentially increased ␣ 1 AR signaling in the compromised heart would be insensitive to the elevated GRK2 levels associated with heart disease. This may provide a mechanism that attempts to maintain cardiac output in response to catecholamines. This lack of GRK2 effect on ␣ 1 ARs could lead to enhanced Gq signaling responsible for the initial adaptive hypertrophy response in the compromised heart. Testing these hypotheses will be the subject of future studies.
In summary, results from this study definitively demonstrate that GRK3 desensitizes ␣ 1B AR-mediated signaling in vivo, whereas the highly homologous GRK2 had no effect on signaling through this G protein-coupled receptor. These results illustrate that although in vitro studies set the foundation for understanding receptor-kinase interactions, in vivo studies are required to fully elucidate in vivo selectivity. Furthermore, it is becoming clear from Tg studies that GRK2, GRK3, and GRK5 play distinct roles in the normal regulation of myocardial signaling and function.
